Asset Details
Do you wish to reserve the book?
A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent
Do you wish to request the book?
A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent
2021
Overview
Effective intervention strategies are urgently needed to control the COVID-19 pandemic. Human angiotensin-converting enzyme 2 (ACE2) is a membrane-bound carboxypeptidase that forms a dimer and serves as the cellular receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ACE2 is also a key negative regulator of the renin–angiotensin system that modulates vascular functions. We report here the properties of a trimeric ACE2 ectodomain variant, engineered using a structure-based approach. The trimeric ACE2 variant has a binding affinity of ~60 pM for the spike protein of SARS‑CoV‑2 (compared with 77 nM for monomeric ACE2 and 12–22 nM for dimeric ACE2 constructs), and its peptidase activity and the ability to block activation of angiotensin II receptor type 1 in the renin–angiotensin system are preserved. Moreover, the engineered ACE2 potently inhibits SARS‑CoV‑2 infection in cell culture. These results suggest that engineered, trimeric ACE2 may be a promising anti-SARS-CoV-2 agent for treating COVID-19.
Engineered soluble trimeric ACE2 constructs with intact enzymatic activity and high affinity to SARS-CoV-2 spike are shown to inhibit viral infection in cellular assays.
Publisher
Nature Publishing Group US,Nature Publishing Group
Subject
/ 631/45
/ 631/535
/ 82
/ ACE2
/ Affinity
/ Angiotensin-converting enzyme 2
/ Angiotensin-Converting Enzyme 2 - chemistry
/ Angiotensin-Converting Enzyme 2 - genetics
/ Angiotensin-Converting Enzyme 2 - therapeutic use
/ Antiviral Agents - chemistry
/ Antiviral Agents - therapeutic use
/ Biomedical and Life Sciences
/ COVID-19
/ Dimers
/ Enzymes
/ Humans
/ Recombinant Proteins - chemistry
/ Recombinant Proteins - genetics
/ Recombinant Proteins - therapeutic use
/ Renin
